scholarly journals Diarrhea as an Initial Presentation in Patients with Medullary Thyroid Cancer: Delaying the Diagnosis

2020 ◽  
Vol 14 (2) ◽  
pp. 391-401
Author(s):  
Mohamed K.M. Shakir ◽  
Andrew J. Spiro ◽  
Vinh Q. Mai ◽  
Thanh D. Hoang
Keyword(s):  
Thyroid Cancer ◽  
Metastatic Disease ◽  
Thyroid Surgery ◽  
Medullary Thyroid Cancer ◽  
Chronic Diarrhea ◽  
Medullary Thyroid ◽  
Other Substances ◽  
Gastrointestinal Motor ◽  
Circulating Levels ◽  
Motor Disturbances

Tumoral secretion of various molecular factors, such as calcitonin (Ct), can cause diarrhea in patients with medullary thyroid cancer (MTC). We report 3 patients (age 26–38 years, serum Ct levels ranging from 2,890 to 52,894 ng/L) with chronic diarrhea, and the diagnosis of MTC was delayed. Diarrheal symptoms improved after thyroid surgery. Two patients with elevated Ct had no diarrhea. The link between tumor humoral secretion and diarrhea is not well established in patients with MTC. Diarrhea is more common in patients with metastatic disease and improves after resection of the tumor. Diarrhea may result from elevated circulating levels of Ct or other substances, such as prostaglandins or serotonin. Other proposed mechanisms include decreased absorption in the colon secondary to gastrointestinal motor disturbances. In conclusion, MTC should be considered when evaluating chronic diarrhea.

scholarly journals SUN-595 Chronic Diarrhea as a Manifestation of Medullary Thyroid Cancer

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Mohamed Shakir ◽  
Harris Baloch ◽  
Vinh Mai ◽  
Thanh Hoang
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Chronic Diarrhea ◽  
Medullary Thyroid

Medullary Thyroid Cancer: Options for Systemic Therapy of Metastatic Disease?

2006 ◽  
Vol 24 (11) ◽  
pp. 1653-1655 ◽  
Author(s):  
Renato G. Martins ◽  
Joseph G. Rajendran ◽  
Peter Capell ◽  
David R. Byrd ◽  
David A. Mankoff
Keyword(s):  
Thyroid Cancer ◽  
Metastatic Disease ◽  
Systemic Therapy ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid

scholarly journals Carcinoembryonic antigen should be concurrently checked with calcitonin to identify distant metastases in medullary thyroid cancer

2020 ◽  
Vol 7 (1) ◽  
pp. IJE27
Author(s):  
Rui Zheng-Pywell ◽  
Anish Jacob Cherian ◽  
Macie Enman ◽  
Herbert Chen ◽  
Deepak Abraham
Keyword(s):  
Thyroid Cancer ◽  
Carcinoembryonic Antigen ◽  
Retrospective Analysis ◽  
Metastatic Disease ◽  
Medullary Thyroid Cancer ◽  
Distant Metastases ◽  
Single Institution ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Additional Imaging

Aim: This study investigates if serum calcitonin or carcinoembryonic antigen (CEA) levels can differentiate between locoregional and metastatic medullary thyroid cancer. Methods: A single institution retrospective analysis was performed on 88 patients with medullary thyroid cancer between 2008 and 2014. Results: In M0disease, calcitonin (p < 0.001) and CEA (p = 0.003) significantly decreased postoperatively. Not only was the correlation significant between calcitonin and CEA preoperatively (r = 0.72; p < 0.001) and postoperatively (r = 0.68; p < 0.001), calcitonin could extrapolate CEA levels (p < 0.001). These findings were statistically insignificant in metastatic disease. Conclusion: Independently, calcitonin and CEA fail to differentiate between locoregional and metastatic disease. Both are essential for prognostication: loss of concordance is suspicious for metastatic disease. Hence, discordant CEA and calcitonin levels should be an indication to pursue additional imaging.

scholarly journals Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer

2012 ◽  
Vol 6 ◽  
pp. CMO.S7999 ◽  
Author(s):  
Nils Degrauwe ◽  
Julie Ann Sosa ◽  
Sanziana Roman ◽  
Hari A. Deshpande
Keyword(s):  
Thyroid Cancer ◽  
Metastatic Disease ◽  
Medullary Thyroid Cancer ◽  
Locally Advanced ◽  
Cancer Syndrome ◽  
Medullary Thyroid ◽  
Costs Of Treatment ◽  
Long Term Prognosis ◽  
New Treatments

Medullary thyroid cancer (MTC) represents an aggressive form of thyroid malignancy. Some may occur spontaneously or can be associated with Multiple Endocrine Neoplasia syndromes, or Familial Medullary Thyroid Cancer syndrome. In these patients, the protooncogene RET (rearranged during transfection) is mutated. In patients who have unresectable or metastatic disease, the long term prognosis is poor. New treatments for this disease have focused on the use of targeted agents that inhibit the receptor tyrosine kinase of RET. One of these treatments, Vandetanib (Caprelsa, Astra Zeneca), recently has received approval from the Food and Drug Administration for the treatment of patients with progressive locally advanced and/or metastatic disease. This review highlights the studies that led to the drug's approval, and discusses on the potential financial costs of treatment and side effects of this therapy. The main clinical studies evaluating Vandetanib for the treatment of other solid tumors will also be reviewed.

Abstract #1101 The Value of Calcitonin Calcium Stimulation Test Levels as Predictors of Medullary Thyroid Cancer.

2018 ◽  
Vol 24 ◽  
pp. 273-274
Author(s):  
Corin Badiu ◽  
Mara Baet ◽  
Ruxandra Dobrescu ◽  
Andra Caragheorgheopol ◽  
Corneci Cristina
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Stimulation Test ◽  
Medullary Thyroid ◽  
Calcium Stimulation

Immunoscintigraphy in Medullary Thyroid Cancer Using an 123I- or 111ln-Labelled Monoclonal Anti-CEA Antibody Fragment

1986 ◽  
Vol 25 (06) ◽  
pp. 227-231 ◽  
Author(s):  
Chr. Eilles ◽  
W. Spiegel ◽  
W. Becker ◽  
W. Börner ◽  
Chr. Reiners
Keyword(s):  
Bone Marrow ◽  
Thyroid Cancer ◽  
Potassium Iodide ◽  
Medullary Thyroid Cancer ◽  
Elevated Serum ◽  
Antibody Fragment ◽  
Special Importance ◽  
Medullary Thyroid ◽  
Medullary Cancer ◽  
Serum Cea

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

Sign in / Sign up

Export Citation Format

Share Document